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Abstract Heritable connective tissue diseases comprise a
heterogeneous group of multisystemic disorders that are
characterized by significant morbidity and mortality. These
disorders do not merely result from defects in the amount or
structure of one of the components of the extracellular
matrix, as the extracellular matrix also serves other func-
tions, including sequestration of cytokines, such as trans-
forming growth factor beta (TGFβ). Indeed, disturbed
TGFβ signaling was demonstrated in several heritable con-
nective tissue diseases, including syndromic forms such as
Marfan or Loeys-Dietz syndrome and non-syndromic pre-
sentations of thoracic aortic aneurysm/dissection. Because
of these findings, new therapeutic targets have been un-
veiled, leading to the initiation of large clinical trials with
angiotensin II type 1 receptor antagonists that also have an
inhibiting effect on TGFβ signaling. Here, we present an
overview of the clinical characteristics, the molecular find-
ings, and the therapeutic strategies for the currently known
syndromic and non-syndromic forms of thoracic aortic an-
eurysm/dissection.
Keywords Heritable connective tissue disease . Thoracic
aortic aneurysm .Marfan syndrome . Loeys-Dietz
syndrome . TGFβ signaling
Introduction
The extracellular matrix (ECM) is a highly organized
multimolecular structure that is indispensable for the
normal functioning of organ systems. Heritable connec-
tive tissue diseases (HCTD) comprise a heterogeneous
group of multisystemic disorders that result from genetic
defects affecting normal ECM assembly and mainte-
nance. HCTD are characterized by significant morbidity
and mortality [43]. Up to now, most genes shown to be
implicated in HCTD encode structural connective tissue
proteins, such as collagens, fibrillin and fibronectin, or
enzymes involved in the biosynthesis or processing of
those proteins. It has been generally assumed that
defects in the amount or structure of one of these
ECM components affect normal organization and struc-
tural integrity of the supporting connective tissues and
result in the typical weakness of bones, skin, vascular
or other tissues, which characterizes the individual dis-
ease phenotypes. During the past decade, however, this
viewpoint was found to be an oversimplification. This
became apparent when other functions were discovered
for the ECM, exemplified by the sequestration function
for TGFβ [36], and the identification of various non-
structural genes for HCTD [5, 22, 26, 29]. This implies
that the pathogenesis of HCTD and the organization of
the ECM are far more complex than originally thought.
Thus, the current perception of the ECM is that of a
complex network that, besides its mechanical role in
providing strength and support to the tissues, also acts
as an important reservoir for cytokines and growth
factors implicated in cellular proliferation, differentia-
tion, migration, and survival and thus has an important
regulatory function in the development and homeostasis
of body organs and tissues [43]. Interestingly, this fresh
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view on ECM function has provided new means of
therapeutic intervention. Originally, when ECM was
assigned a merely structural role, the only putative
therapy was replacement of the deficient ECM compo-
nent by gene therapy, something that seemed unachiev-
able. Nowadays, however, with the recognition of a
regulatory function for ECM components, intervening
in the relevant regulatory pathways using (existing)
pharmaceuticals may provide a plausible therapeutic ap-
proach in case of deficiency of an ECM component. As
such, some HCTD, including Marfan (MFS) and Loeys-
Dietz (LDS) syndromes, and related disorders have
evolved from “incurable” genetic disorders (apart from
surgical interventions) towards diseases in which hopes
for new therapies have risen. Therefore, we will focus
this review on these HCTD and leave other HCTDs
including the Ehlers-Danlos syndromes (EDS, with the
exception of vascular EDS), skeletal dysplasias, osteo-
genesis imperfecta, pseudoxanthoma elasticum and
others largely untouched. For these HCTD, we would
like to refer to other recent reviews [9, 13, 33, 49].
Marfan syndrome
The Marfan syndrome (MFS; MIM#154700) is an auto-
somal dominant HCTD that occurs in approximately 1/
5,000 individuals. It is a multisystemic disorder, mainly
affecting the skeleton (long bone overgrowth, pectus
deformity, and arachnodactyly), the eyes (lens disloca-
tion), and the cardiovascular system. Cardiovascular pa-
thology includes aortic root dilatation primarily at the
level of the sinuses of Valsalva, dissection, and rupture,
and is the leading cause of mortality [46]. Other car-
diovascular manifestations include mitral valve prolapse,
mitral regurgitation, (supra)ventricular arrhythmias, and
systolic and diastolic left ventricular functional impair-
ment. Each of these cardiovascular complications may
present as early as infancy or may not be diagnosed
until adulthood [54]. Other extra-cardiovascular manifes-
tations include dural ectasia, striae distensae, recurrent
inguinal hernias, pneumothorax, and lung emphysema.
In 1991, FBN1 (encoding fibrillin-1, a structural com-
ponent of the microfibrils) was identified as the gene
responsible for MFS [11]. Up to now, several hundred
FBN1 mutations have been identified throughout the
entire gene, but no major correlation between the nature
of the mutation and the clinical phenotype has emerged
[27]. Moreover, despite the presence of identical FBN1
mutations, a remarkable intrafamilial variability is ob-
served, in addition to a marked interfamilial variability,
which has led to the hypothesis that modifier genes must
be involved.
Until recently, the clinical diagnosis was based on the
Ghent nosology [8], but since its revision in 2010 [30],
clinical geneticists have adopted the new version [12, 40,
44]. The revised Ghent nosology puts more weight on
cardiovascular manifestations, ectopia lentis, and molecular
FBN1 testing and summarizes the diagnostic decision mak-
ing in a few simple rules depending on the absence or the
presence of a family history [30].
Originally, it was assumed that the pathophysiology of
MFS was due to structural deficiency of fibrillin-1, leading
to weakened microfibrils. This hypothesis provided a plausi-
ble explanation for the vascular pathology and the lens dislo-
cation, but other features such as skeletal overgrowth and
thickening of the cardiac valves remained unexplained. Sub-
sequently, the study of MFS mouse models suggested an
important role for the cytokine transforming growth factor
beta (TGFβ) in the pathogenesis of MFS; Fbn1 deficient mice
showed increased TGFβ activation and signaling and TGFβ
antagonism rescued various MFS phenotypes [19, 36, 37].
The current pathogenetic model for MFS therefore suggests
that the fibrillin-1 deficient state leads to dysregulation of the
TGFβ signaling cascade. Although historically, studies have
focused on canonical TGFβ signaling, growing evidence now
shows that non-canonical signaling pathways such as those
involving the MAPKs (mitogen-activated protein kinases),
including the extracellular signal-regulated kinase (ERK1/2)
and the Jun N-terminal kinase (JNK) also have an important
role in aneurysm development [20].
Loeys-Dietz syndrome
In 2005, a novel autosomal dominant HCTD with wide-
spread systemic involvement was described by Loeys and
Dietz. The Loeys-Dietz syndrome (LDS; MIM#609192) is
typically characterized by the triad of hypertelorism (widely
spaced eyes), bifid uvula/cleft palate, and arterial tortuosity
with aortic aneurysm and dissection [29]. Additional mani-
festations include craniosynostosis, Chiari malformation,
club feet, patent ductus arteriosus, and aneurysms/dissection
throughout the arterial tree. LDS type 1 patients present with
typical craniofacial features (craniosynostosis, cleft palate,
or hypertelorism), while LDS type 2 patients mostly lack the
craniofacial features but present with cutaneous findings
(velvety and translucent skin, easy bruising, and atrophic
scars). Despite some clinical overlap with MFS, including
aortic aneurysm, arachnodactyly, pectus deformity, dural
ectasia, and scoliosis, LDS patients do not present with
significant long bone overgrowth or lens dislocation. Aneu-
rysm development in LDS is more aggressive compared to
that observed in MFS, i.e., on average, dissection and rup-
ture occur at younger ages and at smaller aortic diameters
than in MFS patients leading to a mean age at death of
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26.0 years [32]. This implies that earlier surgical interven-
tion (at smaller aortic diameters than in MFS patients) is
indicated. Clinicians should also be aware of the increased
risk of pregnancy-related complications. So far, no set of
minimal diagnostic criteria have been established for LDS
and the diagnosis should thus be confirmed through molec-
ular genetic testing.
LDS is caused by mutations in genes encoding trans-
forming growth factor-beta receptor 1 or 2 (TGFBR1 or
TGFBR2) [29]. No clinical distinction can be made be-
tween TGFBR1 or TGFBR2 mutation carriers. Compara-
ble to MFS, a remarkable inter-individual and
intrafamilial clinical variability is observed. The mutations
mainly affect the serine-threonine kinase domain of both
receptors and lead to loss-of-function. Interestingly and
paradoxically, TGFβ signaling was enhanced in aortic
walls and fibroblast cultures of LDS patients [29]. After
the finding of increased TGFβ signaling in a MFS mouse
model [36], the discovery that mutations in TGFBR1/2
were the cause of another aneurysmal syndrome and the
fact that these loss-of-function mutations led to a para-
doxical activation of TGFβ signaling provided further
proof for an important role of TGFβ signaling in aneur-
ysma development [29].
Other disorders in the MFS/LDS spectrum
The aneurysm-osteoarthritis syndrome or Loeys-Dietz
syndrome, type 1C
Van de Laar et al. [51] recently described another HCTD,
designated aneurysms-osteoarthritis syndrome (AOS) or
Loeys-Dietz syndrome, type 1C (MIM#613795). AOS is
characterized by aneurysms, dissections, and tortuosity
throughout the arterial tree in addition to craniofacial (includ-
ing hypertelorism and abnormal palate/uvula), skeletal (in-
cluding arachnodactyly and scoliosis), and cutaneous
(including striae and velvety skin) features and thus perfectly
fits in the phenotypic spectrum of LDS. A distinguishing
feature, however, is the presence of early-onset osteoarthritis.
AOS is caused by mutations in the gene encoding SMAD3, a
component of the canonical TGFβ signaling pathway
[51–53]. Again, dysregulation of TGFβ signaling was dem-
onstrated when studying aortic walls from AOS patients. All
investigated markers of TGFβ signaling, including pSMAD2,
SMAD3, and CTGF (connective tissue growth factor) were
significantly increased in these tissues [51].
Vascular Ehlers-Danlos syndrome
EDS comprises a clinically and genetically diverse group of
HCTD, characterized by congenital fragility of the
connective tissues. The Villefranche nosology recognizes
six subtypes based on clinical characteristics, inheritance
pattern, biochemical, and molecular findings [1]. The
most common types of EDS are the classic, the hyper-
mobile and the vascular type, while the kyphoscoliotic,
the arthrochalasis, and the dermatosparaxis type are
rather rare. Here, we restrict ourselves to the vascular
type of EDS (MIM#130050) since the latter is associat-
ed with a high risk for life threatening complications
and as a consequence with a decreased life expectancy.
We refer to a recent review for details on the other EDS
types [9].
Typical clinical manifestations of vascular EDS include
thin, translucent skin, characteristic facial appearance, vas-
cular fragility demonstrated by extensive bruising and
easy bleeding and spontaneous arterial/intestinal/uterine
ruptures [43]. Vascular EDS is caused by mutations in
COL3A1 (type III collagen α-chain 1) [47]. These muta-
tions consist mostly of missense mutations that lead to the
substitution of essential glycine residues within the triple
helical domain of the type III collagen chain. Interestingly,
in a cohort of 40 patients displaying a vascular EDS-like
phenotype but normal collagen III biochemistry, 30 %
carried TGFBR1/2 mutations [32], suggesting on the one
hand that vascular EDS closely resembles LDS but on the
other hand that TGFBR mutations may cause a broad
spectrum of diseases associated with aortic aneurysms.
To the best of our knowledge, no demonstration of dysre-
gulated TGFβ signaling in vascular EDS has been pub-
lished so far.
Arterial tortuosity syndrome
The arterial tortuosity syndrome (ATS; MIM#208050) is an
autosomal recessive HCTD that is characterized by tortuos-
ity, elongation, stenosis, and aneurysm formation in the
major arteries. Patients often die at a young age. Features
in common with LDS include arachnodactyly, hypertelor-
ism, cleft palate and/or bifid uvula, joint laxity or contrac-
tions, and micro/retrognathia. ATS is caused by loss-of-
function mutations in SLC2A10, encoding GLUT10, which
belongs to the glucose transporter family. ATS has been
associated with enhanced TGFβ signaling, as demonstrated
by increased pSMAD2 and CTGF immunostaining in
patients' arterial walls [5].
Cutis laxa
Hereditary cutis laxa (CL) delineates a heterogeneous
group of rare HCTD, characterized by the presence of
loose, sagging, inelastic skin in addition to systemic
manifestations of variable severity [43]. Both autosomal
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dominant (ADCL) and autosomal recessive forms
(ARCL) exist. ADCL is relatively benign compared to
ARCL. In ADCL, the typical loose, sagging skin can be
accompanied by gastrointestinal diverticulae, hernias, and
genital prolapse. Also, pulmonary artery stenosis, aortic
aneurysm, bronchiectasis, and emphysema may occur.
The major causal gene for ADCL is the elastin gene
(ELN; MIM #123700), while one tandem duplication in
the fibulin-5 gene (FBLN5; MIM#614434) has been de-
scribed as well. Gain-of-function mutations in ELN lead
to ADCL, whereas loss-of-function point mutations or
contiguous gene deletions (involving ELN) give rise to
isolated supravalvular aortic stenosis and Williams-
Beuren syndrome, respectively.
ARCL type 1 (ARCL1) is a life-threatening disorder
characterized by vascular anomalies, lung emphysema,
and diverticulae of the urinary and gastrointestinal tract
aside from the cutaneous manifestations. The prognosis
of ARCL1 is poor as cardiopulmonary failure severely
limits the lifespan of these patients. Mutations in two
fibulin genes, FBLN4 (MIM#614437; also designated
EFEMP2) or FBLN5 (MIM#219100), are responsible
for ARCL1 [21, 28]. Vascular involvement (arterial
aneurysms, arterial tortuosity), however, is most proba-
bly restricted to FBLN4 mutations [6, 42], while the
cutaneous manifestations in FBLN4 patients are limited
and are more pronounced in FBLN5 patients. As such,
ARCL1 caused by FBLN4 mutations can be categorized
within the LDS spectrum.
Another autosomal recessive syndrome, closely re-
sembling ARCL1 and designated Urban-Rifkin-Davies
syndrome (URDS; MIM#613177), was recently shown
to be caused by mutations in LTBP4 [50]. LTBP4
patients present with severe gastro-intestinal and urinary
tract involvement in addition to loose, sagging skin.
Aside from peripheral pulmonary artery stenosis, LTBP4
patients have no vascular involvement. The gene prod-
uct, LTBP4, belongs to the latent transforming growth
factor beta binding proteins (LTBPs), which associate
with TGFβ when secreted into the ECM and keep
TGFβ in its latent form. The latent complexes play an
important role in the regulation of TGFβ-mediated
signaling.
Interestingly, both in ADCL caused by ELN mutations,
ARCL1 caused by FBLN4 mutations and in URDS, dysre-
gulation of TGF-beta signaling was observed [4, 42, 50].
Other types of cutis laxa and related diseases exist
(ARCL2, ARCL3, wrinkly skin syndrome, gerodermia
osteodysplastica, etc.). However, as so far no involvement
of TGFβ signaling has been suggested for these conditions,
we prefer not to go into detail and to refer to a recent review
by Berk et al. [2] for a more thorough description of these
HCTD.
Non-syndromic thoracic aortic aneurysm and dissection
Non-syndromic types of thoracic aortic aneurysms and dis-
sections (TAAD) or types in which only minor additional
features are present exist as well. Occasionally, mutations in
FBN1 [34] and in TGFBR1/2 [48] causing TAAD have been
described, perhaps representing the mildest end of the MFS/
LDS phenotypic spectrum.
In addition, ACTA2 mutations have been identified in
14 % of TAAD patients [16], while MYH11 mutations
have been found in TAAD patients with persistent ductus
arteriosus [56]. Additional symptoms that can be found
in ACTA2 mutation positive patients include persistent
ductus arteriosus, bicuspid aortic valve, iris flocculi, and
cerebrovascular accidents. In fact, ACTA2 mutations can
also cause stroke, Moya-Moya disease, and coronary
artery disease [17]. ACTA2 and MYH11 encode the
smooth muscle cell specific α-actin and β-myosin heavy
chain, respectively. Both proteins are indispensable com-
ponents of the smooth muscle cells contractile apparatus
and mutations in the encoding genes may prevent proper
contraction of the smooth muscle cells. Interestingly,
enhanced TGFβ signaling was demonstrated in aortic
tissue derived from both ACTA2 and MYH11 patients
[41]. Additionally, Gomez et al. [15] found a dysregula-
tion of TGFβ signaling in ascending aortic walls of non-
syndromic thoracic aneurysm patients.
Recent new findings
From the above, a rule seems to have emerged: TGFβ
signaling is significantly associated with both syndromic
and non-syndromic types of thoracic aortic aneurysms.
More importantly, as TGFβ antagonism can attenuate or
prevent the various phenotypes, a causal relationship seems
highly plausible. However, the URDS, one of the disorders
mentioned above, is an exception to this rule, i.e., enhanced
TGFβ signaling was found, but URDS patients do not
present with thoracic aortic aneurysms. Here, a few addi-
tional examples are elaborated to illustrate that increased
TGFβ signaling does not always lead to thoracic aortic
aneurysm development and that the overall picture is thus
far more complex.
In the stiff skin syndrome (SSS; MIM#184900), a rare,
autosomal dominant condition of congenital scleroderma
(thickened skin) associated with short stature, domain-
specific FBN1mutations have been identified. All mutations
were positioned in two FBN1 exons that encode the fourth
TGFβ binding protein-like domain (TB4). This domain
contains the RGD (arginine–glycine–aspartic acid) motif,
which mediates integrin binding. SSS patients do not show
the typical MFS symptoms, including long bone
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overgrowth, thoracic aortic aneurysms, ectopia lentis and
joint laxity; nor do MFS patients ever present with skin
fibrosis. Still, increased TGFβ concentration and signaling
was observed in the dermis of SSS patients [31]. Given the
restricted nature of the mutations and limited affected organs
observed in SSS (mainly skin), it was hypothesized that SSS
mutations may lead to a gain-of-microfibrillar-function,
while most MFS mutations clearly result in loss of function
[31].
Recently, mutations restricted to two exons encoding
the TB5 domain of FBN1 were shown to lead to acro-
micric (AD; MIM#102370) and autosomal dominant
geleophysic dysplasia (GD; MIM#614185) [24]. Both
syndromes are characterized by severe short stature,
short extremities, and stiff joints. Thoracic aortic aneur-
ysms are not part of the phenotypic spectrum, although
cardiac valves stenosis and insufficiency have been as-
sociated with GD. As such, the AD and GD spectrum
again opposes the MFS spectrum. Still, enhanced TGFβ
signaling was demonstrated irrefutably in fibroblasts of
these patients. As AD had been shown previously to be
caused by mutations in ADAMTSL2 [25] and a direct
interaction between FBN1 and ADAMTSL2 was found,
the authors suggested that a dysregulation of the FBN1/
ADAMTSL2/TGFβ interrelationship lay at the basis of
the AD/GD phenotypes.
These few examples further illustrate the complexity of
the TGFβ signaling pathways and their regulatory levels.
Most likely, several factors, including the nature and the
location of the mutation, the nature of the affected gene
product, its spatiotemporal expression levels and the influ-
ence of other paracrine or autocrine factors influence the
final outcome. Additional research will thus be necessary to
understand all contributing factors in order to be able to
predict aneurysm formation.
Treatment strategies
Traditionally, management of MFS patients consisted of a
regular evaluation of their aortic diameters and therapeutic
treatment with beta-blockers [45]. For MFS patients, surgi-
cal intervention is indicated when the aortic diameter
exceeds 5 cm or when the aneurysmal growth exceeds
1 cm/year. For LDS, surgical intervention at smaller aortic
diameters is recommended. In addition, as the aneurysms in
LDS patients can be found throughout the arterial tree, more
extensive imaging is mandatory.
Interestingly, the identification of enhanced TGFβ sig-
naling in MFS mouse models has led to the identification
of losartan as an exciting new possible therapy for MFS
[18, 19], as losartan also has an inhibiting effect on
TGFβ signaling besides being an antagonist of the
angiotensin II type 1 receptor. Indeed, losartan outper-
formed the beta-blocker atenolol when applied to a MFS
mouse model [19]. This exiting finding led to a prelim-
inary observational study in seventeen pediatric MFS
patients in whom other therapy had failed to prevent
progressive aortic root dilatation [3]. These patients were
treated with losartan during 12 to 47 months, leading to
a reduction in rate of aortic root diameter growth from
3.54±2.87 mm/year to 0.46±0.62 mm/year. As this pre-
liminary study had provided proof that losartan can be
efficient in human patients as well, several large, ran-
domized clinical trials on MFS patients have been initi-
ated since. A first trial is comparing atenolol with
losartan in approximately 600 MFS patients during a
3-year period. Unless the trial is stopped early for treat-
ment benefit, results can be expected by 2014 [23].
Additional trials with various designs and inclusion cri-
teria are currently ongoing in Belgium, France, Italy, The
Netherlands, Taiwan, and the United Kingdom [10, 14,
35, 39]. The next few years will thus reveal whether
losartan will become the preferred therapeutic in MFS
patients.
Because of the less frequent nature of related disor-
ders with aneurysm formation and TGFβ signaling
upregulation (LDS, AOS, ATS, ADCL, ARCL1,
TAAD), it is unlikely that large, randomized trials can
be organized for these conditions. For these rarer con-
ditions, evidence may be gathered through the study of
relevant animal models, after which cautious treatment
of patients may be considered. Prudence is indeed called
for, because in contrast to the findings in thoracic aortic
aneurysms, it was shown in a validated mouse model of
abdominal aortic aneurysm formation (Ang II-induced;
[7]), that TGFβ activity actually protects against aortic
aneurysm progression and that TGFβ neutralization pro-
motes aortic aneurysm formation [55].
Although no causal treatment exists for EDS, prophy-
lactic measures are essential, in particular for the vas-
cular type of EDS because of its serious nature.
Individuals with vascular EDS should avoid contact
sports and isometric exertion (like weightlifting). Usage
of anti-coagulentia and other agents that interfere with
platelet function should also be avoided. Likewise, in-
vasive procedures, including angiography, catherizations
and surgical interventions are contra-indicated. Recently,
it was demonstrated that the beta-blocker celiprolol
could prevent major complications in patients with vas-
cular EDS [38], giving new hope for treatment of this
devastating condition.
Much of the information that we have reviewed here, is
also summarized in Table 1 (clinical synopsis) and Fig. 1
(defects within components of the ECM and the TGFβ
signaling pathway).
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Fig. 1 Defects within components of the ECM and the TGFβ signaling pathway leading to various HCTD. The defective components are indicated
with a red cross and the respective diseases are listed in the vicinity of the relevant cross
Table 1 Synopsis of the clinical features
Disorder/syndrome Gene Cardiovascular Skeletal Eye Cutaneous Cranio-facial
Aneurysm Tortuosity Other
Marfan FBN1 +++ − MVP +++ +++ + +
Loeys-Dietz TGFBR1/2 +++ ++ BAV, PDA ++ ++ ++ ++
Aneurysms-osteoarthritis SMAD3 +++ ++ BAV, PDA ++ + ++ ++
Vascular Ehlers-Danlos COL3A1 ++a − + − ++ ++
Arterial tortuosity syndrome SLC2A10 + +++ PS + ++ + ++
Autosomal dominant cutis laxa ELN + − − − +++ ++
Autosomal recessive cutis laxa type 1 FBLN4 ++ ++ + − ++ ++
Autosomal recessive cutis laxa type 1 FBLN5 − − SVAS, PS − − +++ +
Urban-Rifkin-Davis LTBP4 − − PS − − +++ ++
Thoracic aortic aneurysm/dissection ACTA2 +++ − BAV, PDA − +c +d −
Thoracic aortic aneurysm/dissection MYH11 +++ − PDA − − − −
Stiff skin syndrome FBN1 − − − ++b − +++ −
Acromicric/geleophysic dysplasia FBN1 − − AS ++b − ++ ++
Geleophysic dysplasia ADAMTSL2 − − AS ++b − ++ ++
a Vascular fragility
b Short stature instead of long stature
c Iris flocculi
d Livedo reticularis
MVP mitral valve prolapse; BAV bicuspid aortic valve; PDA patent ductus arteriosus; PS pulmonary artery stenosis; SVAS supravalvular aortic
stenosis; AS aortic stenosis
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